THE CORPORATE REPUTATION OF THE PHARMA INDUSTRY IN 2015: THE PERSPECTIVE OF 139 PATIENT GROUPS  with an interest in DIABETES (3rd edition)

Report published by PatientView

8th August 2016

 

COMPANIES ASSESSED FOR ...

  1. Patient centricity.
  2. Provision of patient information.
  3. Patient safety.
  4. Usefulness of products.
  5. Record of transparency.
  6. Integrity.

THE 21 COMPANIES ASSESSED ...

AbbVie I Actavis I Amgen I AstraZeneca I Bayer I Boehringer Ingelheim I Bristol-Myers Squibb I Eli Lilly (Lilly) I GSK I Janssen I Menarini I Merck & Co I Novartis I Novo Nordisk I Pfizer I Roche I Sandoz I Sanofi I Servier I Takeda I Teva
 
 

If you would like more information, or would like to get hold of this report, please use contact details below.

Contact: Alex Wyke     Email: report@patient-view.com   Website: http://www.patient-view.com

 

About this report

London, Monday 8th August 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 139 patient groups with an interest in diabetes. The report provides feedback (from the perspective of  these patient groups) on the corporate reputation of the pharma industry during 2015, as well as on the performance of 21 pharma companies at six key indicators that influence corporate reputation. The 2015 results are compared with those from diabetes patient groups in 2014 and 2013, as well as with those from patient groups across all therapy areas in the 2015 survey.

For the purposes of this report, the phrase ‘corporate reputation’ is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.

 

WHAT THE PATIENT GROUPS SAID ...

“En general las personas con alguna patología crónica como es la diabetes valoran positivamente las industrias de biotecnología medica por su labor investigadora. Las compañías farmacéuticas por el contrario tienen un estigma social de explotación come.” (“In general, people with chronic diseases such as diabetes are positive about medical biotechnology industries for their research.”)

—Regional Spain-based patient group specialising in diabetes

 

“There is growing distrust of pharma in light of several recent and dramatic increases in drug prices in the US.”

—Global US-based patient group specialising in diabetes

 

INDUSTRY-WIDE FINDINGS

The 139 patient groups with an interest in diabetes and responding to the 2015 ‘Corporate Reputation of Pharma’ survey were more positive about the pharma industry’s corporate reputation than patient groups in 2015 from any other therapy area (except patient groups specialising in urinary conditions).

 

    As many as 53.7% of the 139 patient groups with an interest in diabetes and responding to the 2015 ‘Corporate Reputation of Pharma’ survey stated that the pharma industry as a whole had an “Excellent” or “Good” corporate reputation that year. In 2014, 47.9% of diabetes patient groups stated the same. The equivalent figure for patient groups from across all therapy areas in 2015 was 44.7%.

    Patient groups with an interest in diabetes ranked the pharma industry 4th out of 8 healthcare-industry sectors for corporate reputation in 2015—ahead of private healthcare, generics, for-profit, and not-for-profit health insurers. In 2014, diabetes patient groups also ranked pharma 4th out of 8 healthcare-industry sectors. Pharma ranked 5th in 2015’s global results.

     

    In 2015, diabetes patient groups were more impressed than patient groups from any other disease area by pharma’s ability to:

    • Ensure patient safety: 65% of the patient groups with an interest in diabetes responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at this activity. The equivalent figure from patient groups across all therapy areas in 2015 was 58%.
    • Be patient centred: 40% of the patient groups with an interest in diabetes responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at this activity. The equivalent figure from patient groups across all therapy areas in 2015 was 34%.
    • Provide services outside its direct business remit: 29% of the patient groups with an interest in diabetes responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at this activity. The figure from patient groups across all therapy areas in 2015 was 26%.
    • Be transparent, and have integrity: 33% and 40% (respectively) of the patient groups with an interest in diabetes responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at these activities. The equivalent figures from patient groups across all therapy areas in 2015 were 26% and 35%, respectively.
    • Manage adverse news about products: 44% of the patient groups with an interest in diabetes responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at this activity. The equivalent figure from patient groups across all therapy areas in 2015 was 35%.er geographic area. The figure from patient groups worldwide in 2015 was 15%.
     

    BUT ...

    Patient groups with an interest in diabetes in 2015 marked the industry down for the following:

    • Only 32% of patient groups with an interest in diabetes thought pharma “Excellent” or “Good” at providing access to clinical trials in 2015. The equivalent figures among diabetes patient groups in 2014 and 2013 were 39% and 33% respectively. The equivalent figure among patient groups across all therapy areas in 2015 was 39%.
    • Comments from 2015’s respondent diabetes patient groups indicate worries about the escalating price of medicines. 14% of diabetes patient groups in 2015 thought that the industry should improve its pricing policies (against only 8.7% of diabetes patient groups in 2014 thinking the same).

     

    HOW INDIVIDUAL PHARMA COMPANIES PERFORMED FOR CORPORATE REPUTATION IN THE SUBJECT AREA OF DIABETES IN 2015

     

    Patient groups with an interest in diabetes ranked Novo Nordisk 1st out of 21 pharma companies for corporate reputation in 2015 (for a second year in a row). Diabetes patient groups also ranked Novo Nordisk 1st on all six indicators of corporate reputation in 2015.

    Notable improvements in overall rankings were reported by Lilly (up to 2nd in 2015 from 3rd in 2014);  Sanofi (up to 3rd from 4th); and Janssen (up to 5th from 9th).

    (In 2014, only 14 companies were assessed, versus 21 in 2015.)

    ABOUT THE RESPONDENTS:

    2015's 139 respondent patient groups with an interest in diabetes came from 41 countries (15 of the 139 were based in Denmark).

     
     

    END OF STATEMENT

    PatientView is a UK-based research organisation that consults closely with patient groups, and publicises the work of the patient-advocacy movement.